B-cell-derived lymphotoxin promotes castration-resistant prostate cancer

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Prostate cancer (CaP) progression involves androgen dependence, with castration-resistant CaP (CRPC) being a major cause of mortality.
• While androgen ablation is a primary therapy, CRPC emerges within months, and its mechanisms are poorly understood.
• The role of inflammation in CRPC development and progression has not been extensively studied.

Purpose of the Study:

• To investigate the role of inflammation in the development of castration-resistant prostate cancer.
• To elucidate the molecular mechanisms by which androgen ablation influences inflammatory responses and CaP cell survival.
• To identify potential therapeutic targets within the inflammatory pathways driving CRPC.

Main Methods:

• Analysis of inflammatory infiltration in CaP during progression and after androgen ablation.
• Investigation of IkappaB kinase (IKK)-beta and NF-kappaB signaling in inflammatory and CaP cells.
• Assessment of cytokine production and activation of IKK-alpha and STAT3 pathways in CaP cells.

Main Results:

• Androgen ablation in androgen-dependent CaP leads to leukocyte infiltration, including B cells.
• IKK-beta activation in leukocytes results in cytokine production.
• These cytokines activate IKK-alpha and STAT3 in CaP cells, promoting hormone-free survival.

Conclusions:

• Inflammation, specifically leukocyte infiltration and activation of the IKK-beta/cytokine/IKK-alpha/STAT3 axis, plays a critical role in promoting castration-resistant prostate cancer.
• Androgen ablation can inadvertently trigger pro-survival inflammatory pathways in CaP cells.
• Targeting these inflammation-driven pathways may offer novel therapeutic strategies for CRPC.